Politecnico di Torino has been awarded the prestigious ERC Advanced Grant
TURIN, Italy, June 17, 2025 (GLOBE NEWSWIRE) -- Politecnico di Torino's research project 'IntelliSwarm' has been awarded the prestigious ERC Advanced Grant, an initiative of the European Research Council aimed at supporting the practical application and exploitation of the results of frontier research projects. This represents a significant opportunity for researchers from across Europe who, in order to participate in the selection process, must be recognised as leaders in their field of research, with a proven track record of excellence that ensures the delivery of original results and a positive impact on the future of society. A total of 281 projects received funding across Europe, including 25 in Italy.
The scientific coordinator of the project is Enrico Magli, Professor at the Department of Electronics and Telecommunications-DET, who will receive €3 million to invest in research over the next five years. By assembling a team of experts and investing in state-of-the-art computing infrastructure, the project aims to increase the quality, availability and timeliness of images processed on board satellites, thereby optimising the use of inter-satellite and satellite-to-ground communication links.
In a world that increasingly needs accurate data to interpret and predict phenomena and events of collective interest – with particular attention to environmental disasters that affect our regions with growing frequency, such as floods and wildfires – the studies conducted by Professor Magli have the ambition of collecting images of the Earth's surface with significantly higher spatial and spectral resolution and 3D reconstruction capabilities. This is achieved through the use of advanced artificial intelligence techniques and processing carried out by a swarm of satellites. The swarm enables cooperation between different satellites, providing a distributed acquisition and calculation paradigm. This has the advantage of overcoming the limitations of a single large satellite and ensuring robustness, as the failure of one satellite does not compromise the functionality of the system as a whole.
Beyond space applications: The methods developed within the project will also be relevant for other types of 'embedded' systems, thereby extending the impact of the research to different fields of investigation, such as sensor networks and the Internet of Things.
'Earth observation from space is a rapidly expanding field with a variety of applications in sustainability, environmental disaster management, and spatial analysis – explains Professor Magli – the 'IntelliSwarm' aims to develop highly sophisticated instruments and modes of observation, distributing their complexity across a large number of small satellites, overcoming the limitations of optics with AI, and running advanced AI models directly on board the satellites. I find the project extremely stimulating because of the scientific problems it will lead us to address, which will also have implications for the use of AI in systems based on low-power computing nodes. Looking ahead, a possible continuation of the project involves training models directly on board the satellites, enabling them to learn continuously from all observed images.'
'This recognition reflects the growing importance of excellence in research within Politecnico,' says Rector Stefano Corgnati. 'Being internationally competitive requires full synergy between experiential learning and increasingly essential research and innovation activities. The opportunities offered by the ERC Advanced Grant will also strengthen our appeal within the international research landscape, laying the groundwork to attract top young talent and enabling them to engage with cutting-edge projects.'
For further information, please visit the official ERC website: https://erc.europa.eu/news-events/news/erc-2024-advanced-grants-results
For more information:- ufficio.stampa@lapresse.it
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e98ad666-566c-4ea7-87b9-65ea71c009ddSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 Meeting
First-in-human, Phase 1 Study of LRK-4189 to Begin in the Fourth Quarter CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness, today announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumors. The announcement was made at a presentation Larkspur was invited to give at the prestigious MEDI First Time Disclosures: Breakthroughs on New Medicines session at ACS Fall 2025, a meeting of the American Chemical Society in Washington, DC. Cancer cells maintain their fitness by developing survival adaptations that foster escape from intrinsic and extrinsic mechanisms of cell death in conditions of stress. Phosphatidylinositol 5-phosphate 4-kinase, type II, gamma (PIP4K2C) is a lipid kinase associated with poor outcomes in a range of cancers including CRC and breast cancers. PIP4K2C is co-opted by cancer cells to increase their fitness by evading immune surveillance and adapting to stress. 'Genetic studies have long highlighted PIP4K2C as a key player in cancer stress adaptation, but its extremely low kinase activity made it resistant to conventional inhibition approaches,' said Catherine Sabatos-Peyton, PhD, CEO of Larkspur Biosciences. 'With our novel degrader, LRK-4189, we've finally unlocked this critical pathway. By reducing cancer cell fitness, triggering intrinsic apoptosis, and engaging the immune system to clear residual tumor cells, LRK-4189 has the potential to overcome the limitations of earlier therapies. We're excited to advance this promising therapy to the clinic later this year.' According to the American Cancer Society, in the United States, approximately 150,000 cases of CRC are diagnosed annually, with MSS CRC accounting for about 85% of all CRC cases. About LRK-4189 LRK-4189 is an orally bioavailable, selective degrader of PIP4K2C with subnanomolar potency in primary human cells. LRK-4189-mediated degradation of PIP4K2C leads to intrinsic cancer cell death and activates interferon signaling, triggering multiple killing mechanisms in difficult-to-treat MSS CRC cells. In vivo, LRK-4189 demonstrates dose dependent PKPD with single agent efficacy in multiple models of CRC and synergy with first-line standard of care chemotherapy. In primary human CRC patient-derived spheroids, 50% of patient samples respond to LRK-4189 with a preferential response in MSS CRC, which compares favorably to benchmark cetuximab in the same platform (35%). Cetuximab may be either a first- or second-line treatment in people with RAS wild type CRC. LRK-4189 has completed IND-enabling studies and expects to initiate a Phase 1 clinical trial in Q4 2025. About Larkspur Biosciences Larkspur Biosciences is pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness. Larkspur develops therapies that decrease cancer cell fitness and sensitizes the cells to intrinsic and immune-driven mechanisms of killing. The company is advancing first-in-class programs that target the adaptations cancer cells use to proliferate, invade tissue, and escape the immune system. LarkX, the company's proprietary bioinformatics platform, couples machine learning with tumor genetics to discover cancer cell fitness pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. Larkspur's founders include Lewis C. Cantley, PhD, professor of medicine at Dana-Farber Cancer Institute, professor of cell biology at Harvard Medical School; Vijay K. Kuchroo, DVM, PhD, professor of neurology at Harvard Medical School, senior scientist at Brigham and Women's Hospital; and Nathanael Gray, PhD, professor of chemical and systems biology at Stanford University. Visit us at and follow us on LinkedIn and X. Media Contact:Dan BoyleScientPRdan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Hepsiburada Submits Amendment to 6-K
ISTANBUL, Aug. 20, 2025 (GLOBE NEWSWIRE) -- On August 15, 2025, D-MARKET Elektronik Hizmetler ve Ticaret Anonim Şirketi (the 'Company') furnished to the Securities and Exchange Commission a Form 6-K (the 'Original Form 6-K') containing certain exhibits relating to the Company's Annual General Assembly Meeting of Shareholders for, and with respect to, the financial year 2024, to be held on September 15, 2025. This Amendment No. 1 to the Original Form 6-K amends the Original Form 6-K solely for the purpose of amending and restating Exhibit 99.4 (Board of Directors' Annual Report for 2024) in its entirety, due to an inadvertent clerical error contained in the version included in the Original Form 6-K. Except as described above, the Original Form 6-K remains unchanged. About Hepsiburada Hepsiburada is a leading e-commerce technology platform in Türkiye, operating through a hybrid model that combines first-party direct sales (1P) and a third-party marketplace (3P) with approximately 100 thousand its vision of leading the digitalization of commerce, Hepsiburada serves as a reliable, innovative and purpose-driven companion in consumers' daily lives. Hepsiburada's e-commerce platform offers a broad ecosystem of capabilities for merchants and consumers including last-mile delivery, fulfilment services, advertising solutions, cross-border sales, payment services and affordability solutions. Hepsiburada's integrated fintech platform, Hepsipay, provides secure payment solutions, including digital wallets, general-purpose loans, buy now pay later (BNPL) and one-click checkout, enhancing shopping convenience for consumers across online and offline while driving higher sales conversions for its founding in 2000, Hepsiburada has been purpose-driven, leveraging its digital capabilities to empower women in the Turkish economy. In 2017, Hepsiburada launched the 'Technology Empowerment for Women Entrepreneurs' program, which has supported approximately 65 thousand female entrepreneurs across Türkiye in reaching millions of customers. Investor Relations Contactir@ Media Contactcorporatecommunications@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Dr. Ritesh Kalra Scholarship to Support Aspiring Medical Professionals
Dr. Ritesh Kalra Scholarship SECAUCUS, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- The Dr. Ritesh Kalra Scholarship for Medical Students is now accepting applications for its 2026 award cycle, offering a $1,000 prize to a deserving undergraduate student on the path to becoming a doctor. Established by acclaimed physician Dr. Ritesh Kalra, this initiative seeks to encourage academic excellence, foster a spirit of compassion in medicine, and provide financial assistance to future healthcare leaders. The scholarship will be awarded through an engaging essay contest, providing applicants with an opportunity to share their vision for the future of medicine. Students are invited to reflect on the balance between technological advancements in healthcare and the human connection that remains at the heart of patient care. The award is open to undergraduate students in accredited institutions who are committed to pursuing a medical career. 'This scholarship represents more than financial assistance—it's a way to inspire the next generation of physicians to uphold both innovation and empathy in their work,' said Dr. Kalra. 'Medicine is not only a science; it's a calling that requires skill, dedication, and a genuine desire to help others.' About Dr. Ritesh Kalra Dr. Ritesh Kalra is a highly respected internal medicine specialist with decades of service in both private practice and hospital settings. His career spans extensive clinical work, award-winning research, and mentorship of medical students. Trained across prestigious institutions in Poland, New York, and Georgia, Dr. Ritesh Kalra has earned repeated recognition as a Top Doctor in Internal Medicine from 2020 through 2025. Fluent in Hindi and Punjabi, he connects with a diverse patient population and has devoted his career to improving healthcare delivery and patient outcomes. His inspiration for creating the scholarship stems from his belief in the power of education and the critical role that young, motivated doctors will play in the future of global health. Application Details The Dr. Ritesh Kalra Scholarship for Medical Students is open to all undergraduate students enrolled in accredited U.S. institutions who are on an academic track toward becoming a physician. Applicants must submit a 750–1,000-word original essay responding to the following prompt: "In the rapidly evolving field of medicine, how can future doctors balance technological advancement with the human connection that lies at the heart of patient care? Share your thoughts, supported by personal experiences, observations, or aspirations." Submissions should demonstrate critical thinking, originality, and a strong personal commitment to the medical field. Important Dates Application Deadline: May 15, 2026 Winner Announcement: June 15, 2026 The winning essay will be selected by the scholarship review committee based on insight, clarity, creativity, and the ability to convey a compelling vision for the future of healthcare. The $1,000 award will be sent directly to the recipient to support their educational expenses. How to Apply Applicants should send their essay along with their full name, contact information, school name, and field of study to apply@ The subject line should read: Dr. Ritesh Kalra Scholarship Application. The scholarship reflects Dr. Ritesh Kalra's ongoing mission to support the academic journeys of aspiring doctors and to encourage them to integrate technological expertise with compassionate care. Through this program, he hopes to inspire students to pursue medicine not only as a career but as a lifelong service to humanity. Contact InformationSpokesperson: Dr. Ritesh KalraOrganization: Dr. Ritesh Kalra Scholarship for Medical StudentsWebsite: apply@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
